AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23913807 — intervention group
Group type: EXPERIMENTAL
Intervention: HF/LED (high-fat low-energy density diet, 1.05 kcal/g)
Number of subjects: 20
Study 23913807 — intervention group
Group type: EXPERIMENTAL
Intervention: HF/HED (high-fat high-energy density diet, 1.60 kcal/g)
Number of subjects: 20
Study 23913807 — intervention group
Group type: EXPERIMENTAL
Intervention: HC/LED (high-carbohydrate low-energy density diet, 1.05 kcal/g)
Number of subjects: 20
Study 23913807 — intervention group
Group type: COMPARATOR
Intervention: HF/HED
Number of subjects: 20
Study 23913807 — intervention group
Group type: COMPARATOR
Intervention: HF/LED
Number of subjects: 20
Study 22435779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (5×30 s maximal sprints)
Number of subjects: 9
Study 22435779 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 9
Study 22435779 — intervention group
Group type: COMPARATOR
Intervention: Walking (30 min brisk walking)
Number of subjects: 9
Study 20105163 — intervention group
Group type: EXPERIMENTAL
Intervention: GR1 (1‐hour, 50‐g glucose screen +/‐ 3‐hour, 100‐g OGTT)
Number of subjects: 1594
Study 20105163 — intervention group
Group type: EXPERIMENTAL
Intervention: GR2 (50‐g GS +/‐ 2‐hour, 75‐g OGTT)
Number of subjects: 1594
Study 20105163 — intervention group
Group type: COMPARATOR
Intervention: GR3 (2‐hour, 75‐g OGTT)
Number of subjects: 1594
Study 17297614 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy (LPT)
Number of subjects: 31
Study 17297614 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (CPT)
Number of subjects: 31
Study 15639634 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of WOMAC osteoarthritis index
Number of subjects: 72
Study 12574898 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg/day) for 1 month
Number of subjects: 111
Study 12574898 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 111
Study 10723222 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgG level against A60 mycobacterial antigen measured by ELISA
Number of subjects: 76
Study 10723222 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (23 total)
Number of subjects: 76
Study 10723222 — intervention group
Group type: COMPARATOR
Intervention: Sarcoidosis patients (20 total)
Number of subjects: 76
Study 10723222 — intervention group
Group type: COMPARATOR
Intervention: Lung cancer patients (17 total)
Number of subjects: 76
Study 10723222 — intervention group
Group type: COMPARATOR
Intervention: Patients with mycobacterial infections other than tuberculosis (8 total)
Number of subjects: 76
Study 8856618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 146
Study 8856618 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (DS)
Number of subjects: 146
Study 1731034 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily maintenance sodium (3 to 4 mEq of sodium per kilogram per day)
Number of subjects: 17
Study 1731034 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction (no sodium supplement other than with treatments such as transfusion)
Number of subjects: 17
Study 6376301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrachlorodecaoxide (TCDO) in a water solution containing glycerin
Number of subjects: 38
Study 6376301 — intervention group
Group type: COMPARATOR
Intervention: Physiological sodium chloride (control)
Number of subjects: 38
Study 31669446 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children intervention (5 vs. 10 sessions, basic vs. enhanced package, on-demand vs. structured supervision)
Number of subjects: 864
Study 31669446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 864
Study 29450890 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600 mg once daily
Number of subjects: 365
Study 29450890 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once daily
Number of subjects: 365
Study 29450890 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control)
Number of subjects: 365
Study 26407253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 61
Study 26407253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early measles vaccination (MV) at age 4.5 months
Number of subjects: 656
Study 24522160 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccination (MV) only at age 9 months
Number of subjects: 656
Study 24522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early MV in healthy children
Number of subjects: 656
Study 24522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early MV in ill children
Number of subjects: 656
Study 22945623 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐mg naltrexone implant and oral placebo (NI+OP group; 102 patients)
Number of subjects: 306
Study 22945623 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant and 50‐mg oral naltrexone hydrochloride (PI+ON group; 102 patients)
Number of subjects: 306
Study 22945623 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant and oral placebo (PI+OP group; 102 patients)
Number of subjects: 306
Study 22945623 — intervention group
Group type: EXPERIMENTAL
Intervention: NI+OP group
Number of subjects: 306
Study 22945623 — intervention group
Group type: COMPARATOR
Intervention: PI+ON group
Number of subjects: 306
Study 22945623 — intervention group
Group type: COMPARATOR
Intervention: PI+OP group
Number of subjects: 306
Study 20012501 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular prediction system based on 22-gene expression profile
Number of subjects: 141
Study 17564826 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry-assisted breathing training for 4 weeks
Number of subjects: 12
Study 17564826 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 12
Study 16030367 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolife Ephedra‐Free
Number of subjects: 20
Study 16030367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (Cervitec) applied every 3 months
Number of subjects: 181
Study 12236827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 181
Study 10085276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg SQV/200 mg RTV
Number of subjects: 20
Study 10085276 — intervention group
Group type: COMPARATOR
Intervention: 1600 mg SQV
Number of subjects: 20
Study 8775777 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal ring
Number of subjects: 0
Study 8775777 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 0
Study 2058588 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus endurance exercise and weight training (EEWT)
Number of subjects: 69
Study 2058588 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus weight training (WT)
Number of subjects: 69
Study 2058588 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus endurance exercise (EE)
Number of subjects: 69
Study 2058588 — intervention group
Group type: COMPARATOR
Intervention: Diet only (C)
Number of subjects: 69
Study 2058588 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (C, EE, WT, EEWT)
Number of subjects: 69
Study 6875802 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-conscious subjects with failure feedback
Number of subjects: 120
Study 6875802 — intervention group
Group type: COMPARATOR
Intervention: High self-conscious subjects with success feedback
Number of subjects: 120
Study 6875802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-conscious subjects
Number of subjects: 120
Study 31097732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for six months
Number of subjects: 75
Study 31097732 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study 31097732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi experts
Number of subjects: 75
Study 29216608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief need based psychoeducation
Number of subjects: 80
Study 29216608 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 29216608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 27085785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT) levels, adjusted for every standard deviation increase (13.2 U/L)
Number of subjects: 679
Study 27085785 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-glutamyl transferase (GGT) >70 U/L
Number of subjects: 679
Study 27085785 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT levels (lower levels)
Number of subjects: 679
Study 27085785 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT >70 U/L
Number of subjects: 679
Study 25134822 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV testing and counselling (PITC)
Number of subjects: 930
Study 25134822 — intervention group
Group type: COMPARATOR
Intervention: Voluntary counselling and testing (VCT)
Number of subjects: 930
Study 21975559 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg IV infusion)
Number of subjects: 0
Study 21975559 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (5 mg/day)
Number of subjects: 0
Study 19843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least one unexplained medication discrepancy
Number of subjects: 210
Study 19843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit card holders
Number of subjects: 210
Study 19843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients prescribed 5 or more drugs at discharge from the ED
Number of subjects: 210
Study 19843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients first seen by a physician within 1 hour of a change in working shift
Number of subjects: 210
Study 19843837 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional minute of wait time for a physician
Number of subjects: 210
Study 17447275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute hamstring muscle massage
Number of subjects: 11
Study 17447275 — intervention group
Group type: COMPARATOR
Intervention: 15-minute prone rest
Number of subjects: 11
Study 15870639 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 12
Study 15870639 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exercise
Number of subjects: 12
Study 15870639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 12
Study 15870639 — intervention group
Group type: COMPARATOR
Intervention: Control (no prior intervention)
Number of subjects: 12
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brainstem responses (ABRs)
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-latency responses (MLRs)
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cortical potentials (SCPs)
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ABRs and MLRs
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ABRs and SCPs
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MLRs and SCPs
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: All three responses (ABRs, MLRs, SCPs)
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: All three responses in patients without neurological signs of brainstem lesion
Number of subjects: 40
Study 12067329 — intervention group
Group type: EXPERIMENTAL
Intervention: All three responses in subjects with negative MRI
Number of subjects: 40
Study 10220831 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary IL‐6 levels in patients with SS
Number of subjects: 36
Study 10220831 — intervention group
Group type: COMPARATOR
Intervention: Salivary IL‐6 levels in patients with dry mouth
Number of subjects: 36
Study 10220831 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL‐6 levels in patients with SS
Number of subjects: 36
Study 10220831 — intervention group
Group type: COMPARATOR
Intervention: Serum IL‐6 levels in patients with dry mouth
Number of subjects: 36
Study 10220831 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 36
Study 10220831 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between salivary IL‐6 levels and focus score of labial biopsies in SS patients
Number of subjects: 36
Study 8538437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory reeducation
Number of subjects: 27
Study 8538437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sensory reeducation)
Number of subjects: 27
Study 2216622 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose surfactant (100 mg/kg of bovine surfactant)
Number of subjects: 75
Study 2216622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose surfactant (100 mg/kg of bovine surfactant, eligible for up to three additional doses)
Number of subjects: 75
Study 2216622 — intervention group
Group type: COMPARATOR
Intervention: Control (air placebo)
Number of subjects: 75
Study 6257524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine synthetic PTH
Number of subjects: 63
Study 6257524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (16 salmon, 18 human, 4 porcine)
Number of subjects: 63
Study 30430605 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan 25 mg twice daily
Number of subjects: 38
Study 30430605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29041947 — intervention group
Group type: EXPERIMENTAL
Intervention: FREE approach (intervention arm GPs trained in the FREE approach)
Number of subjects: 275
Study 29041947 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm GPs continuing to practice as usual)
Number of subjects: 275
Study 29041947 — intervention group
Group type: EXPERIMENTAL
Intervention: FREE approach
Number of subjects: 275
Study 29041947 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study 25468170 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotic treatment
Number of subjects: 351
Study 25468170 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of antibiotic treatment
Number of subjects: 351
Study 23321318 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8h) with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 662
Study 23321318 — intervention group
Group type: COMPARATOR
Intervention: Placebo with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 662
Study 21454051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) course
Number of subjects: 36
Study 21454051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 20031848 — intervention group
Group type: EXPERIMENTAL
Intervention: Information technology-enhanced care coordination
Number of subjects: 550
Study 20031848 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 550
Study 17629162 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon (500 mg twice/daily for six months)
Number of subjects: 20
Study 17629162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin pill)
Number of subjects: 20
Study 15140323 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 47
Study 15140323 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 47
Study 15140323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11249829 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 9622407 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour change interval
Number of subjects: 76
Study 9622407 — intervention group
Group type: COMPARATOR
Intervention: 72-hour change interval
Number of subjects: 76
Study 7982445 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus 50 IU d‐1, 5 days per week of nasal salmon calcitonin
Number of subjects: 100
Study 7982445 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 100
Study 3059222 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 1881 FU (cholinergic nootropic)
Number of subjects: 0
Study 3059222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 239346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg
Number of subjects: 7
Study 239346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 7
Study 239346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 7
Study 239346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 7
Study 239346 — intervention group
Group type: COMPARATOR
Intervention: Propantheline bromide
Number of subjects: 7
Study 31669921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extension contractions at 90° knee flexion
Number of subjects: 52
Study 31669921 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of torque development (0-100 ms)
Number of subjects: 52
Study 31669921 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of torque development (100-200 ms)
Number of subjects: 52
Study 28669778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 80
Study 28669778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac and Rebamipide
Number of subjects: 80
Study 28669778 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone alone
Number of subjects: 80
Study 28669778 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone and Rebamipide
Number of subjects: 80
Study 25819462 — intervention group
Group type: EXPERIMENTAL
Intervention: Retosiban
Number of subjects: 64
Study 25819462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23454402 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 50 μg
Number of subjects: 385
Study 23454402 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 75 μg
Number of subjects: 385
Study 23454402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 22142351 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (80 mg, once daily for 4 weeks)
Number of subjects: 41
Study 22142351 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg, once daily for 4 weeks)
Number of subjects: 41
Study 18647845 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Number of subjects: 418
Study 18647845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, ibuprofen, and/or 4% lidocaine gel
Number of subjects: 418
Study 16832667 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of Robert Jones bandage
Number of subjects: 44
Study 16832667 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of elastic support bandage
Number of subjects: 44
Study 16832667 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of below-knee plaster cast
Number of subjects: 44
Study 16832667 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of synthetic below-knee cast
Number of subjects: 44
Study 16832667 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of all bandages and casts
Number of subjects: 44
Study 12874748 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg per day for 6 weeks
Number of subjects: 15
Study 12874748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy pill)
Number of subjects: 15
Study 11071348 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitions Gray variable tint optics (VTO)
Number of subjects: 59
Study 11071348 — intervention group
Group type: COMPARATOR
Intervention: Clear lenses
Number of subjects: 59
Study 11071348 — intervention group
Group type: COMPARATOR
Intervention: Fixed-tint lenses
Number of subjects: 59
Study 9128016 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E1 (PGE1) at a rate of 0.2 microgram.kg‐1.min‐1 throughout surgery
Number of subjects: 109
Study 9128016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 109
Study 8151248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 106
Study 8151248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 3555016 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (slow‐release aspirin and dipyridamole)
Number of subjects: 38
Study 3555016 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B (Control group)
Number of subjects: 38
Study 30373567 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid-treated group
Number of subjects: 150
Study 30373567 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 150
Study 27261997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepeta menthoides Boiss. & Buhse freeze-dried aqueous extract
Number of subjects: 72
Study 27261997 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 72
Study 24100074 — intervention group
Group type: EXPERIMENTAL
Intervention: Taloelast(®) anterior elastic ankle-foot orthoses
Number of subjects: 7
Study 24100074 — intervention group
Group type: COMPARATOR
Intervention: Shoes only
Number of subjects: 7
Study 22924259 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to guidelines (British National Formulary - BNF, and Senford Guide)
Number of subjects: 100
Study 22924259 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treatment
Number of subjects: 100
Study 20426630 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerlink stent‐graft
Number of subjects: 157